For investors aiming to profit from momentum, a method that joins solid core business progress with a positive technical arrangement can be an effective tactic. This process selects for firms displaying solid basic expansion, specifically in earnings and revenue, while also showing a technical chart formation that indicates a possible rise from a time of sideways movement. The aim is to find stocks where better business basics may be near the point of being acknowledged by the wider market, possibly resulting in a notable price adjustment. A main instrument for this study is ChartMill’s joined screening, which can find securities fitting these particular technical and basic measures.
TG Therapeutics Inc (NASDAQ:TGTX) offers an example for this investment tactic. The biotechnology firm, centered on treatments for B-cell malignancies and autoimmune diseases, displays a notable mix of very high progress measures and a technical chart that seems to be tightening before a shift.
Very High Basic Progress
The foundation of this tactic is finding companies with excellent progress, and TG Therapeutics meets this point clearly. Based on its basic analysis report, the firm gets a high Progress Rating of 8 out of 10. The last year has been a change, led mainly by the introduction and sale of its multiple sclerosis therapy, BRIUMVI®.
- Revenue Jump: The firm’s revenue increased by a notable 87.32% over the past year. Even more notable is the multi-year view, showing a compounded yearly progress rate of 426.73%.
- Earnings Increase: Matching the top-line jump, Earnings Per Share (EPS) rose greatly by 257.14% in the last year.
- Future Predictions: Experts expect this solid momentum to persist, with forward guesses forecasting average yearly EPS progress of 52.96% and revenue progress of 25.78% over the next years.
This progress outline is vital for the tactic, as continued, high-speed expansion is frequently a forerunner to major stock price gains if the firm can keep its path.
Supporting Basics: Earnings and Money Condition
While progress is the main force, the tactic also needs "acceptable earnings and condition" to make sure the progress is lasting and not built on a weak money base. TG Therapeutics’s reports show a moderate view here.
- Earnings (Rating: 5/10): The firm has lately become profitable, a major turning point. Its earnings margin of 72.56% and operating margin of 20.01% are some of the top in the biotechnology field. However, the rating is balanced by a past of negative money flows as the firm spent heavily on its commercial introduction, a normal stage for biotech companies moving to sales.
- Money Condition (Rating: 5/10): The firm keeps a solid cash position with a current ratio of 4.10, showing good ability to meet short-term needs. It has a workable debt amount, adding to a good Altman-Z score that indicates a low close-term chance of money trouble. This money steadiness gives the space required to keep following its progress tactic.
A Technical Arrangement Ready for Shift
The basic story is only one part of the situation. The technical study shows a stock that has been absorbing its large gains and may be making a base for its next shift. TG Therapeutics gets a high Arrangement Rating of 8 out of 10, which finds interesting chart formations.
- Sideways Movement Phase: After a major climb following its commercial introduction, the stock has used recent months trading in a sideways band between about $26 and $31. This time of lower change and flat action can often end in a strong directional shift.
- Main Block Level: The study finds a clear block area between $29.23 and $29.76, made by a mix of trendlines and main average lines. A clear move above this area on high volume could mark the end of the sideways movement and the start of a new upward path.
- Market Setting: It is significant that this possible arrangement is happening while the stock’s short and long-term paths are still called negative and it is behind the wider S&P 500. This difference between a solid business recovery and a trailing stock price is exactly the type of pressure that a breakout tactic looks to use.
Value Points
The value view is mixed, which is expected for high-progress biotech stocks. The firm’s Price-to-Earnings (P/E) ratio seems high in simple terms but is actually less costly than almost 90% of its field peers. More importantly, its low PEG ratio, which includes its very high earnings progress rate, suggests the stock may be fairly valued when its progress path is thought about. This matches with the progress investment idea that higher values can be accepted by higher progress.
End
TG Therapeutics shows the kind of chance a joined progress-and-arrangement search plans to locate. The firm is in the middle of a basic change, moving from a research-stage body to a commercial progress story with very fast revenue and earnings gains. Technically, the stock seems to be finishing a needed sideways movement phase, gathering force near a clear block level. For investors using this tactic, a verified move above the $29.76 block could be seen as a sign that the market is starting to revalue the stock to match its new progress outline.
Interested in locating more stocks that join solid progress with interesting technical formations? You can use the same search with our Solid Progress Stock Technical Arrangements Search Tool.
Disclaimer: This article is for information only and does not make up money advice, a suggestion, or a deal to buy or sell any securities. Investing includes risk, including the possible loss of main. Always do your own study and think about talking with a skilled money advisor before making any investment choices.